Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293088 | 0.78 | ALDH1A1 (0.63) | KDM4ETSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL4544154 | 0.76 | KDM4E (1.00) | KDM4EDAOTSHRGRIN2DGRIN3B | |
| SCHEMBL3863268 | 0.76 | KDM4E (0.61) | KDM4ETSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL173688 | 0.76 | KDM4E (0.61) | KDM4ETSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5137768 | 0.76 | KDM4E (0.61) | KDM4ETSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL827223 | 0.72 | — | — | |
| SCHEMBL6249816 | 0.72 | KDM4E (0.61) | KDM4ETSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL20945207 | 0.72 | KDM4E (0.61) | KDM4EDAOTSHRGRIN2DGRIN3B | |
| SCHEMBL4912309 | 0.72 | KDM4E (0.56) | KDM4ETSHRLMNAGRIK1GRIA1 | |
| SCHEMBL4057148 | 0.72 | KDM4E (0.61) | KDM4ETSHRGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415345-B | Pyridazinone-based broad-spectrum anti-influenza inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| WO-2014115080-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
| US-4131677-A | Anti-inflammatory oxazolo [5,4-b]pyridines | MERCK & CO., INC. (US) | 1978-12-26 | — | — | US | disclosed |
| US-4038396-A | ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | KDM4E 4225/4885DAO 4055/4885DYRK1A 3110/4885 |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | KDM4E 1753/4885DAO 2005/4885DYRK1A 1048/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | KDM4E 4225/4885DAO 4055/4885DYRK1A 3110/4885 |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | TP53, MDM4, MDM2 | KDM4E 2728/4885DAO 2476/4885DYRK1A 1752/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | KDM4E 4225/4885DAO 4055/4885DYRK1A 3110/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | KDM4E 1753/4885DAO 2005/4885DYRK1A 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.